title: Combined modality treatment using BID radiation for locally advanced non-small cell lung carcinoma.
abstract: BACKGROUND
  From February 1988 to August 1991, 82 patients were treated on Phase II trial of split-course multimodality treatment for locally advanced, non-small cell lung cancer (NSCLC).
  
  
  METHODS
  Treatment consisted of twice-daily radiation (150 cGy/fraction) delivered with concomitant infusional cisplatin, etoposide, and fluorouracil for 1 week every third week. Patients were classified before initial treatment as either potentially resectable (eligible for surgery [ES]) or ineligible for surgery (IES). The ES group consisted of 38 Stage IIIA and 7 Stage IIIB patients. The IES group had 5 patients staged as IIIA and 32 staged as IIIB. Most patients were staged clinically. ES patients received three cycles of treatment (39 Gy) before resection. IES patients received four cycles (60 Gy) delivered with curative intent.
  
  
  RESULTS
  Thirty-nine of 45 ES patients underwent resection. The pathologic response rate was 27%. Three-year actuarial local control was 86% for 41 evaluable ES patients. Three-year actuarial survival for the whole ES group was 39%, with a median follow-up for living patients of 32 months. The IES group faired less well, with an 18% 3-year actuarial survival. Treatment was well tolerated with a median weight loss of one-half pound, mild or moderate pneumonitis in 5%, mild esophagitis in 15%, and severe nausea and/or vomiting in 10% of patients. Treatment-related mortality was 5%.
  
  
  CONCLUSIONS
  Patients treated with conventional radiation alone for Stage III NSCLC are rarely cured. This well tolerated Phase II study demonstrated encouraging results for such patients. Both local control and survival appeared promising, especially in patients rendered resectable after combined-modality treatment.
authors.affiliation: Division of Radiation Oncology, City of Hope National Medical Center, Duarte, CA 91010.
authors.forename: M A
authors.initials: MA
authors.lastname: Taylor
authors.forename: S
authors.initials: S
authors.lastname: Reddy
authors.forename: M S
authors.initials: MS
authors.lastname: Lee
authors.forename: P
authors.initials: P
authors.lastname: Bonomi
authors.forename: S G
authors.initials: SG
authors.lastname: Taylor
authors.forename: E
authors.initials: E
authors.lastname: Kaplan
authors.forename: P L
authors.initials: PL
authors.lastname: Faber
authors.forename: W
authors.initials: W
authors.lastname: Warren
authors.forename: F R
authors.initials: FR
authors.lastname: Hendrickson
mesh_terms: D000328:Adult; D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011879:Radiotherapy Dosage